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The discovery of prion disease transmission in mammals, as well as a non-Mendelian type of inheritance in yeast, has led to the establishment
of a new concept in biology, the prion hypothesis. The prion hypothesis postulates that an abnormal protein conformation propagates itself in an
autocatalytic manner via recruitment of the normal isoform of the same protein as a substrate, and thereby acts either as a transmissible agent of
disease (in mammals) or as a heritable determinant of phenotype (in yeast and fungus). Although reconstitution of fully infectious PrPSc in vitro
from synthetic components has not yet been achieved, numerous lines of evidence indicate that the prion protein is the major and essential
component, if not the only one, of the prion infectious agent. This article summarizes our current knowledge about the chemical nature of the prion
infectious agent, describes potential strategies and challenges related to the generation of prion infectivity de novo, proposes new hypotheses to
explain the apparently low infectivity observed in the first synthetic mammalian prions, and describes plausible effects of chemical modifications
on prion conversion.
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been associated with the formation of ordered protein aggregates
[1,2]. A common feature among all “conformational” diseases is
the conversion of a protein into highly ordered polymeric forms
with crossβ-sheet rich structures [3]. Among neurodegenerative
disorders, however, the prion maladies were placed into a
special category for the following reason. In addition to sporadic
and familial forms, which are common for other neurodegen-
erative maladies, prion disease can also be infectious. Ironically,
while prion researchers have been struggling to provide definite
proof that the prion protein transmits the disease, otherAbbreviations: PrP, prion protein; PrPC, cellular isoform of the prion protein;
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lopathy; GdnHCl, guanidine hydrochloride; Tg, transgenic
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doi:10.1016/j.bbadis.2006.07.007amyloidogenic proteins have been shown to be competent in
transmitting certain neurodegenerative or systemic diseases in a
prion-like manner [4–6].
1. Biochemical nature of prion infectivity
The prion hypothesis states that the infectious agent of prion
diseases is an abnormally folded isoform of the prion protein
(PrPSc) that replicates its abnormal conformation [7,8]. Because
reconstitution of an efficient in vitro replication system using
purified or synthetic components has not yet been achieved,
substantial effort has been spent on identifying possible cellular
cofactors that might be involved in prion conversion. It is still
not clear whether any other cellular components are essential
for prion replication and what role they may play. Hypothe-
tically, these cellular components could be divided into two
large categories: (i) co-factors that are important for stabilizing
PrPSc structure and, therefore, are a constituent part of PrPSc;
and/or (ii) co-factors that are required for conversion from PrPC
to PrPSc, but are not necessarily incorporated into PrPSc
aggregates.
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of an α-linked polyglucose have been shown to be permanent
components of prion rods purified from scrapie brains [9,10].
Approximately 5–15% of PrPSc is composed of polysacchar-
ides, which are believed to form a structural scaffold. This
scaffold should have a significant impact on the accessibility of
PrPSc to proteolytic digestion and its half-life in a cell [9]; it
might also impact strain diversity. In addition to polysacchar-
ides, small amounts of sphingolipids and cholesterol were found
in purified preparations of prion rods, which is not surprising
considering that lipids represent the cellular environment for
prion conversion [11].
After nearly two decades of searching, the attempts to
identify nucleic acids as constituent components that are either
essential for prion infectivity or specify strain-dependent
properties have not been successful [12,13]. While not essential
for prion infectivity, nucleic acids might play some role in a
complex process of prion conversion. Recent studies showed
that antibody to DNA immunocaptured PrPSc in brain
homogenates, suggesting that PrPSc might have high affinity
for binding to nucleic acids [14]. The functional role of the
PrPSc–DNA complex needs to be clarified in future studies, as it
remains uncertain whether this complex is formed in vivo, or is
only present in homogenized tissues. Another study that
exploited an in vitro conversion assay suggested that RNA
molecules might be involved in facilitating prion replication
[15]. Considering that RNAs were supplied at 100–1000-fold
excess over the amount of PrPSc to the conversion reactions, and
that the stimulating effect of RNAs was shown to be sequence
independent [16], it is unlikely that RNAs serve as a catalyst of
prion replication. The stimulating effects of RNA are more
related to its polyanionic nature. Other classes of polyanions
including sulfated polysaccharides were also found to stimulate
prion conversion in a cell-free system [17]. Polyanions may
provide a frame for aligning PrPC and PrPSc molecules in a
mutually favorable orientation. To date, the search for cellular
cofactors that might be involved in prion replication is still
going on.2. Two strategies for de novo generation of prion infectivity
in vitro
There are many technical challenges related to the generation
of prion infectivity in vitro. Despite substantial conformational
differences between PrPC and PrPSc (PrPC is a PK-sensitive
α-helical monomer, whereas PrPSc is an assembled multimer
characterized by enhanced resistance to PK-digestion and an
increased amount of β-structure [18,19]), it is still unclear
which physical property can be used as a valid probe for
monitoring the formation of PrPSc de novo in a cell-free
system. Several recent studies have shown that the correlation
between PK-resistance and prion infectivity that appeared to
be well established in older studies is, in fact, not absolute
[20–23]. It is well known that acquiring a β-sheet rich
conformation by PrP molecules or aggregation into insoluble
fibrillar states are also not exclusively associated with thegeneration of prion infectivity [24,25]. The fact that PrPSc is
intrinsically polymorphic and heterogeneous raises an addi-
tional skepticism as to whether any single physical property
could be exploited as an in vitro marker of infectivity. It will
be beneficial if future work determines whether a combination
of physical properties such as a unique pattern of surface-
exposed epitopes distinguishes the infectious subpopulation of
PrP from the broad range of abnormally folded non-infectious
PrP states.
In an attempt to generate the infectious PrP forms, two
different strategies have been pursued: (i) PrPSc-dependent
conversion or amplification [26–28], and (ii) conversion of
PrPC or recombinant PrP (rPrP) in the absence of a PrPSc
template [24,29,30]. Because cell-free amplification of PrPSc
has been discussed in several other review articles [31], here we
will focus on the second approach.3. In vitro conversion of recombinant PrP or PrPC in the
absence of PrPSc
This approach has more parallels with the sporadic
formation of prions, rather than with prion diseases acquired
through transmission. In opposition to the amplification
approach, where the physical properties of the newly
generated PrPSc are expected to mimic that of PrPSc seeds,
the conversion reaction in the absence of PrPSc seeds poses
uncertainty regarding the conformation of the final products
of the reaction. To monitor conversion, most researchers have
followed an increase in the PK-resistance or β-sheet rich
structures. It is not surprising that, in the absence of a PrPSc
template, the conversion of rPrP or PrPC produced a large
diversity of abnormal β-sheet rich isoforms, which acquired
some but not all the physical characteristics of PrPSc
[24,25,32–38]. Together, these studies illustrate the intrinsic
propensity of the PrP molecule to adopt a diverse range of
conformations depending on solvent conditions and cofactors
supplemented in the conversion reactions.
3.1. Generation of amyloid fibrils
By analogy to the studies where the amyloid form was
shown to be equivalent to a prion state for several yeast prion
proteins [39–41], converting rPrP into amyloid fibrils seemed to
be one of the possible ways for de novo generation of
mammalian prion infectivity in vitro. For the last few years
several protocols for producing fibrils from rPrP or PrPC have
been developed by different groups. In contrast to yeast prion
proteins in which the amyloidogenic regions are natively
unfolded, the PrP domain associated with mammalian prion
infectivity is structured and thermodynamically stable [42].
Because chemical denaturants and elevated temperatures are the
most common way of manipulating the dynamic balance
between different unfolding intermediate states, it is not
surprising that the first experimental protocols for producing
amyloid fibrils from the structured C-terminal domain of α-rPrP
(rPrP90–231) utilized partially denaturing conditions such as
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temperature and high pressure [36]. Subsequently, Riesner and
co-workers established an alternative conversion procedure,
where amyloid fibrils were produced by incubating rPrP90–
231 or PrPC in the presence of low concentrations of sodium
dodecyl sulfate or in the presence of lipids [43,44]. Under
partially denaturing conditions, amyloid fibrils were produced
from both oxidized [29,38] and reduced forms of rPrP90–231
[24,33]. Our recent studies demonstrated that the full-length
rPrP also converts into the fibrillar form under partially
denaturing solvent conditions [45]. The lag-phase for the
polymerization kinetics was shorter for the full-length rPrP
relative to that of rPrP90–231 [46,47], suggesting that the
unstructured N-terminal region facilitated this process. The lag-
phase was also shown to be dependent on the procedure for
preparation of rPrP stock solution even when the conversion
reactions were carried out under identical partially denatured
conditions, an observation that is not yet fully understood [48].
3.2. Synthetic mammalian prions
The most stringent criteria for judging whether prion
infectivity is generated in vitro de novo is a bioassay in
animals. There have been no reports showing the production of
infectious prions in vitro with an infectivity titer high enough to
cause disease directly in wild type animals [43]. Our former
studies demonstrated, however, that the transmissible form of
prion disease could be induced in transgenic mice that
expressed PrP89–231 at high levels (Tg 9949) by inoculation
with amyloid fibrils generated in vitro from rPrP89–230
[29,49]. These fibrils did not cause disease within 600 days
when inoculated directly into wild type mice. However, after the
first passage in Tg 9949, the synthetic prions could be
transmitted to both Tg 9949 and to wild type animals in a
second passage [49]. Similarly to the fibrils formed from
rPrP89–230, a chemically synthesized 55-residue peptide
(residues #90–145) harboring a P101L mutation and refolded
in vitro into a β-conformation has also induced disease in
transgenic mice that express PrP(P101L) [50]. Opposite to the
Tg 9949 mice, however, the Tg PrP(P101L) mice were found to
develop disease spontaneously even in the absence of synthetic
peptide [51]. Tg 9949 mice did not develop any clinical signs of
spontaneous disease, nor they produced transmissible scrapie
upon aging. Furthermore, unique biochemical and neuropatho-
logical features indicated that a novel strain of TSE evolved
in Tg 9949 mice inoculated with fibrils [52]. The disease-
associated PrP conformer identified in Tg PrP(P101L) mice
inoculated with the synthetic 55-residue peptide, however,
was conformationally indistinguishable from those found in
the same Tg mice that developed disease spontaneously [21].
Taken together these data argue, that the 55-residue peptide
accelerated a slowly progressing, spontaneous form of the
disease, while the fibrils of rPrP89–230 caused prion disease
de novo.
The incubation times observed upon inoculation of fibrillar
rPrP89–230 were much longer than those exhibited by most
known PrPSc strains. Considering that the length of incubationtime is typically used as a measure of prion infectivity titer (in
the assay that is referred to as the incubation time assay), a
hasty conclusion has been made that synthetic prions exhibited
a very low infectivity titer. While such conclusion would be
valid if one is testing the infectivity of natural TSE strains that
have been well adapted to a particular host, the attempts to fit
the data from transmission of synthetic prions into simple
equations does not appear to be well justified. Nevertheless, a
number of questions have to be addressed. Why, despite high
expression levels of PrP89–231 in Tg 9949, does long
incubation time precede the progression of prion disease? In
what aspect are amyloid fibrils produced from rPrP89–230
deficient as infectious agent?
While searching for an explanation for the long incubation
time, it is important to acknowledge that the natural strains of
PrPSc evolved through natural selection and evolution [53].
Natural TSE strains might appear as a result of selection and
evolution of different conformational subtypes of PrPSc of
sporadic origin. Only those strains that show a very fast rate
of replication and, correspondingly, shorter incubation times
have a chance to ‘survive’ in the natural environment and are
also preferred by many laboratory investigators. Moreover,
most strains that are currently used in laboratories were
passaged numerous times and are well adapted to a particular
host. For instance, in 1977 Kimberlin and Walker described
an experimental model of scrapie in hamsters in which the
incubation period decreased progressively over the first 4
passages before becoming stable at the 5th and subsequent
passes [54]. Therefore, the long incubation time observed in
testing the in vitro-generated fibrils would not be surprising at
all if one considers that no selective pressure was applied to
the synthetic prions produced in a plastic tube. For the above
reasons, the first synthetic prions may simply fall into a
category of very slow propagating strains. One can argue,
however, why then did the incubation time become much
shorter in subsequent passages of synthetic prions? Here, we
propose two hypotheses referred to as the ‘maturation’ and
‘adaptation’ hypotheses, each of which equally well reconcile
this paradox. These hypotheses might guide future studies on
production of the next generation of synthetic prions.
3.3. The ‘maturation’ hypothesis
This hypothesis speculates that the amyloid fibrils generated
in vitro are not yet mature prions, but rather correspond to a
semi-infectious (i.e. with low specific infectivity) metabolic
intermediate referred to as PrP*, which is on the pathway to
PrPSc (Fig. 1a) [55]. Our previous studies revealed that the
amyloid fibrils are more PK-sensitive than ‘classical’ PrPSc;
therefore, further conversion steps or cellular cofactors might be
required for acquiring a proper PK-resistant conformation
[55,56]. Specifically, we identified three major PK-resistant
fragments in the amyloid form. These fragments encompassed
residues 138/141–230, 152/153–230, and 162–230; these
fragments remained assembled in fibrillar structures after PK-
treatment and maintained high β-sheet content with high
seeding activity as determined in a cell-free conversion assay
Fig. 1. Two hypotheses explaining the long incubation time observed for the first
passage of synthetic prions. (a) The ‘maturation’ hypothesis postulates that the
amyloid fibrils generated in vitro correspond to an intermediate form (PrP*),
which is on the pathway of conversion from PrPC to PrPSc. As yet unidentified
cellular cofactors may be required for maturation. (b) The ‘adaptation’
hypothesis postulates that efficient propagation of synthetic prions in the first
passage is precluded due to an apparent transmission barrier. Transmission
barriers arise because the subset of fibrillar conformers that are generated from
rPrPs in vitro does not overlap with the subset of PrPSc strains produces in vivo.
The differences in the incubation time in the first and second passages of the
synthetic prions are attributed to conformational adaptation.
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amyloid fibrils generated at high concentrations of PK were
similar to the PK-resistant fragments found in patients with
sporadic CJD [57]. Furthermore, PrPSc exposed to partially
denaturing conditions (2.5 M GdnHCl) displayed a similar
PK-resistant core, where the C-terminal regions (residues
∼140–230) remained intact [58]. Therefore, the C-terminal
PK-resistant fragments found in sporadic CJD and produced
in vitro might be proteolytic products of PrP*, a metabolic
intermediate or a byproduct of formation of ‘classical’ PrPSc.
If it is true, the long lag-phase observed in the first passage of
amyloid fibrils simply reflects the additional incubation time
required for conversion of PrP* into mature PrPSc.
It remains to be determined whether any molecules assist the
maturation and production of infectious prions. In summary, the
‘maturation’ hypothesis assumes that the amyloid fibrils (or
PrP*) and PrPSc have similar substructure, and that maturationmay involve interaction with as yet unknown cellular co-factors
that stabilize PK-sensitive regions of PrP*.3.4. The ‘adaptation’ hypothesis
The ‘adaptation’ hypothesis postulates that the shortening
of incubation times observed in the second passage of
synthetic prions may be attributed to conformational adapta-
tion to the host suggesting that an apparent transmission
barrier precludes efficient propagation of the synthetic prions
in the first passage (Fig. 1b). A transmission barrier is
typically observed when the sequence of PrPSc in the
inoculum does not match that of PrPC in the recipient animals
[59–62]. Besides the differences in the sequences of PrPs
between recipient and donor species, other factors such as
strain-specific conformational differences also contribute to
the transmission barrier. Noteworthy, the complex behavior of
transmission of different scrapie strains was described in
1960s and 70s, long before the prion-only concept of prion
propagation was introduced. Pattison and Jones showed that
passage of a scrapie strain which is well adapted to mouse
through other species resulted in modification of strain
properties [61]. In other studies, Kimberlin and Walker
recognized that the ‘adaptation’ of scrapie strains transmitted
from a donor to acceptor species may involve the selection of
a single strain from a mixture and/or modification of strain
properties [63]. Modification of strain properties could be
temporal or permanent depending on transmission path in the
subsequent passages [64]. Since then, different strains of prion
disease have been found to have significantly different
propensities to overcome the transmission barrier, presumably
as a result of different conformations of PrPSc [65,66].
Furthermore, some but not all recipient species can propagate
certain strains from donor species [62].
Using animal models of prion transmission, an intimate
link between the species barrier and the strain phenomenon
has been well established in the last several years. The
biophysical mechanism of this unique phenomenon and the
folding rules that control the strain-specificity of the species-
barrier have yet to be discovered. Fig. 2 illustrates a
framework that provides some insight into the strain-
specificity of the species barrier. This framework helps to
explain on a very simplistic level why some strains from
donor species can be transmitted to recipient species, while
other strains cannot; and why some but not all recipient
species can propagate certain strains from donor species. This
model also predicts that an intermediate passage through a
third species might be necessary for successful transmission of
some strains from one species to other species.
What factors cause an artificial ‘in vitro–in vivo’ transmis-
sion barrier in propagation of synthetic prions? Because the
sequence of rPrP89–230 in the amyloid fibrils was identical to
that of endogenously expressed PrPC (mouse PrP89–230), it is
likely that the apparent transmission barrier arises due to the
unique conformational properties of the fibrils. Specifically, in
contrast to the classical PrPSc, the fibrils generated in vitro
Fig. 2. The new conceptual framework postulates that (i) the primary structure of
PrP of each individual species (A, B, and C) determines to large extent the
conformational diversity of PrPSc strains. (ii) The particular conformation
occupied by newly generated PrPSc within a given conformational space is
specified by PrPSc seeds or templates. (iii) Subsets of conformers (strains) formed
by PrP's from different species may overlap suggesting that some PrPSc strains
are more universal and can be shared by two or more species, whereas other
strains are more species-specific. For instance, strain n is shared by speciesA,B,
and C, while strain m is shared by species A and C. Only those strains that
occupy overlapping areas can be propagated by more than one species.
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residues 90–138 [55], (ii) the lack of glycosylation and GPI
anchor, and (iii) the unusually high conformational stability of
the cross-β-sheet fibrillar core [55]. Each of these three factors
individually or all together could contribute to the appearance
of an artificial in vitro–in vivo transmission barrier and the
necessity for conformational adaptation.
Resent studies, however, argued that the GPI anchor has
minimal, if any, impact on prion infectivity. Removal of the
GPI anchor from mature PrPSc did not reduce prion
infectivity [67]. Furthermore, anchorless PrPSc generated in
GPI-deficient mice in the form of amyloid fibrils was
shown to be highly infectious [68]. While the GPI anchor
seems to be unessential for acquiring an infectious
conformation, the possible impact of glycosylation is less
certain. For instance, in the absence of carbohydrates the
steric constraints that might have been imposed on the
packing of the polypeptide chain in the cross β-sheet
fibrillar core in vivo is removed. Therefore, in the fibrillar
state, carbohydrates-deficient PrP molecules may adopt a
conformation different from the disease-specific conforma-
tions formed from PrPC in the cell.
The unusually high conformational stability of the in vitro
generated fibrils is another factor that is likely to contribute to
the ‘in vitro–in vivo’ transmission barrier. The conformational
stability of fibrils can be estimated from a solvent-induced
denaturation experiment, from which the C1/2 value is
calculated (C1/2 is the concentration of GdnHCl at which
50% of fibrils are folded and 50% are unfolded as estimated
from the two-state folding model). Unexpectedly, consistentwith synthetic mammalian prions, low infectivity of amyloid
fibrils produced from yeast prions was linked to their high
conformational stability. A possible relationship between the
conformational stability and fibril infectivity represents an
emerging concept in yeast and mammalian prions and,
therefore, will be discussed in the next chapter.4. Does conformational stability control the infectivity of
amyloid fibrils?
Recent studies revealed a strong link between conforma-
tional stability and infectivity of amyloid fibrils formed by the
yeast prion protein Sup35 [41]. The amyloid fibrils that
displayed low conformational stability were found to exhibit a
high efficiency of infection with the large majority of colonies
showing a strong phenotype (‘strong’ strains) [41]. Vice versa,
fibrils that had high conformational stability displayed low
infectivity and produced ‘weak’ strains. In yeast prions, the
weak strains are defined as those strains that disappear fast or
that could be easily cured, whereas the strong strains are
characterized by their ability to sustain fast growing colonies for
a long period of time.
A similar correlation between conformational stability and
infectivity was identified in our experiments with synthetic
mammalian prions. In contrast to yeast prions, however, the
apparent infectivity of mammalian prions is judged by the
length of the incubation time, but not from the efficiency of
infection. When tested in GdnHCl-induced denaturation
experiments, the amyloid fibrils of rPrP 89–230 generated in
vitro displayed an unusually high C1/2 value of 4.1 M [55]. The
same C1/2 value was observed for MoSP1 (Mouse Synthetic
Prion strain 1) formed in Tg9949 mice upon inoculation of
fibrillar rPrP 89–230, when very long incubation time of 516
days was observed [49]. Therefore, the high C1/2 value for
MoSP1 correlated well with the unusually long incubation time;
this C1/2 value was substantially higher than those found for
other prion strains. In GdnHCl-induced denaturation, most of
the ‘natural’ prion strains exhibited C1/2 values between 1 M
and 2.5 M [69]. Remarkably, the second passage of MoSP1
resulted in substantial shortening of the incubation time from
516 days to only 258 days. Such dramatic change in the
incubation time was accompanied by a substantial decrease in
the conformational stability of MoSP1 as reflected by a change
in the C1/2 value from 4.2 M to 1.7 M GdnHCl (Fig. 3). Both,
the shortening of the incubation time and a decrease in
conformational stability, are signs of the conformational
adaptation of MoSP1, resulting in a C1/2 and the length of the
incubation time similar to that observed for ‘natural’ prion
strains.
These studies suggest that the intrinsic infectivity of fibrils
might be controlled, at least in part, by the conformational
stability of the cross-β-sheet core (Fig. 3). The molecular
mechanism that accounts for the correlation between con-
formational stability and intrinsic infectivity has yet to be
explored. Conformational stability is likely to be linked to the
mechanical properties of fibrils such as their intrinsic fragility,
Fig. 3. Schematic illustration of energy landscape of the prion conversion. The
conformational space occupied by PrPSc strains (red dots) produced from
PrPC in vivo is limited and does not overlap with the space occupied by
amyloid fibrils (green dots) generated from non-glycosylated rPrP in vitro.
Fibrils produced in vitro (‘weak’ strains) are conformationally more stable
than PrPSc (‘strong’ strains), therefore, conformational adaptation requires a
walk ‘up-hill’.
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Because fragility controls the rate of multiplication of active
centers in prion replication [47], the conformational stability
should have a direct impact on intrinsic infectivity. While
shaking and sonication are known to fragment prion fibrils invitro [28,47], the cellular mechanism responsible for PrPSc
fragmentation in vivo is unknown.
The new concept that the rate of prion replication and the
length of the incubation time are, to a large extent, depends
on the conformational stability of the cross-β-fibrillar core
has direct implication for many issues in the prion field
including the generation of prion infectivity in vitro. If this
new concept is correct, the efficient replication of synthetic
prions in vivo was precluded because of the high
conformational stability of Mo rPrP 89–230 fibrils produced
in vitro (Fig. 3). From the perspective of a free energy
landscape, conformational adaptation requires a walk ‘up-
hill’, from a thermodynamically most stable amyloid confor-
mation toward a less stable but biologically more relevant
form (Fig. 3).
As a concluding note, it is important to mention that the
‘maturation’ and ‘adaptation’ hypothesis are different in one key
aspect. The ‘maturation’ hypothesis postulates that amyloid
fibrils or PrP* generated in vitro have a substructure very
similar to that of PrPSc, and that this substructure is largely
preserved upon maturation of PrP* into PrPSc. The ‘adaptation’
hypothesis, on the other hand, suggests that the amyloid fibrils
are primitive surrogates of PrPSc and that the substructure of
amyloid fibrils may change dramatically in the course of
adaptation. The ‘maturation’ and ‘adaptation’ hypotheses are
not mutually exclusive of each other. Future studies should
determine whether either of above hypotheses is correct.5. Chemical modifications
The effect of chemical modification on prion conversion has not been given full consideration in the past. Limitations in the
sensitivity of techniques utilized for detecting protein modifications and difficulties in working with insoluble PrPSc isolates account
in part for gaps in our knowledge [70].
Chemical modifications of the proteins are similar to point mutations; therefore, their effect on the protein secondary structure and
susceptibility to conformational changes could be dramatic. While prion diseases are believed to result from conformational changes
in prion protein, changes in primary structure such as those caused by chemical modifications may play an important role in
individual susceptibility to the disease and the rate of disease progression.
The most common spontaneous chemical modifications to proteins are oxidative damage, side chain amide hydrolysis and
reactions with electrophiles. Various enzymatic modifications are also present. Due to their longer lifetime in the cells, protein
aggregates (such as PrPSc) often accumulate more chemical modifications compared to other cellular proteins. It us unclear,
however, whether modifications occurred before or after conversion to PrPSc and whether they have any effect on the
conversion. Prion replication is a highly cooperative process, and even a small subpopulation of modified PrPC could have a
substantial impact on kinetics and product distribution of this process [71]. While several types of chemical and enzymatic
modifications have been detected in PrPSc [72,73] (methionine oxidation, aspartate deamination, AGE adducts, proline
hydroxylation), the list is probably incomplete. Further studies employing newly developed sensitive techniques should be able
to address the questions that have been difficult to study in the past. Here we will survey the most common types of
spontaneous modification in PrP and other amyloidogenic proteins and their known effects on conversion into disease-related
forms.
5.1. Oxidative damage
Oxidation of the proteins is a common process in biological systems [74]. While glutathione serves as a natural antioxidant
in vivo, its levels decrease with age and protein oxidation becomes more prevalent. Methionines are considered the most
reactive amino acids but oxidation can also impact histidines, tyrosines, tryptophans and other residues. Methionine is usually
oxidized to the methionine sulfoxide [75].
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a drastic effect on protein structure due to a much higher polarity and lower flexibility of methionine sulfoxide compared to the
methionine side chain itself [76].
Methionine oxidation was shown to inhibit fibrillation of several amyloidogenic proteins such as α-synuclein [77,78] and Aβ
[79,80]. Oxidation of methionines in PrPC is a common process in vivo since PrPC is present in an environment rich with reactive
oxygen species [81,82]. Not surprisingly, oxidized methionines have been found in PrPSc, although it is not clear whether the
oxidation occurred during handling of the PrPSc isolates [73]. Methionine residues in the central region of PrP (residues 90–140)
are especially prone to oxidation [83]. Methionine oxidation interferes with fibril formation from the peptide corresponding to
residues 106–126 of PrP [84] and from full-length rPrP [71]. Furthermore, oxidation of methionines in preformed rPrP fibrils was
shown to inhibit conformational rearrangement of the region 90–140 into PrPSc-like PK-resistant state [56,71]. This inhibition can
be attributed to perturbation of the structure of 90–140 region by methionine sulfoxides. Because some methionines in PrP
occupy positions essential for species barrier and the number and location of methionines in PrP depend on the species [85],
oxidation of these residues could play a role in development or alteration of the species barrier for PrPSc inter-species
transmission.
In addition to methionines, tyrosines are also subject to oxidative modifications such as nitration and dimerization. Spontaneous
or peroxidase-mediated nitration of tyrosine with peroxynitrite leads to 3-nitrotyrosine [86].This modification decreases the pKa of the tyrosyl hydroxyl group from 10.1 to 7.2 making a significant percentage of
nitrotyrosines negatively charged at physiological pH. Low levels of nitrotyrosines were shown to promote fibril formation from
α-synuclein [87] and tau protein [88]. Oxidative dimerization of tyrosines is usually caused by their reactions with reactive
oxygen species, often metal-catalyzed [74].Nitrotyrosines or tyrosine dimers have not been detected in PrPC or PrPSc but their presence at low levels cannot be ruled out.
PrPSc-dimers are often seen in SDS-PAGE performed under strongly reducing conditions. Whether these dimers appeared due to
formation of intermolecular disulfide bonds or due to tyrosine dimerization remains uncertain. The effects of these modifications
on other proteins suggest that they might promote PrPSc formation.
5.2. Deamidation
Deamidation of the side chains of asparagines and glutamines is relatively common under physiological conditions [89]. This
reaction proceeds via a complex mechanism, and both rate and product distribution is dependent on protein sequence and secondary
structure.
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neutral amino acids (Asn, Gln) to negatively charged ones. Like oxidation, this is a significant change in protein structure similar to
point mutation and may influence protein fibril formation. Deamidated asparagines and glutamines have been found in paired helical
filaments formed by the tau protein [90]. Deamidation of Asn107 has been observed in rPrP upon prolonged storage [91,92] and in
PrPSc [93]. In rPrP this modification leads to increased protein aggregation in the presence of copper ions [91]. It is unclear whether
low levels of this modification found in PrPSc (0.5%) had any impact on PrPSc formation [93]. Nonetheless, prion polymerization is a
highly cooperative process, and Asn107 is located in the region of PrPC that is believed to be essential for acquiring an infectious
conformation [94–96].
5.3. Reactions with aldehydes
Reducing sugars (glucose, fructose) and sugar-derived aldehydes (methylglyoxal, glyoxal) can reversibly react with amino groups
of the proteins (Lys, Arg, N-termini) to form Schiff base adducts. Slow rearrangement of these adducts can lead to more stable
Amadori products and further to the heterogeneous set of adducts known as advanced glycation end-products (AGEs) [97,98].
Due to slow turnover of proteins within amyloid deposits it is not surprising that AGE adducts are present in many protein
fibrils in vivo [98–100]. In addition to disruption of the protein structure, these modifications can also lead to protein
crosslinking. Crosslinking by AGEs may have multiple effects including stabilization of aggregated forms and acceleration of
polymerization [101–103].
Similar to other protein deposits, prion plaques contain AGEs [104], which are believed to be carboxymethyl adducts. These
modifications have been localized to lysine (Lys 23, Lys 24, Lys 27) and arginine (Arg 37) residues in N-terminal region of
700 I.V. Baskakov, L. Breydo / Biochimica et Biophysica Acta 1772 (2007) 692–703PrPSc [72]. Earlier sequencing studies have also suggested a modification at Arg 25 in both PrPC and PrPSc [105], although its
nature was unclear at that time.
Highly reactive aldehydes (e.g. 4-hydroxy-2-nonenal and malondialdehyde) are also produced by lipid peroxidation [106].
Their adducts were found in deposits of serum amyloid A [107] and tau protein [108]. Effects of these aldehydes on the prion
protein have not been investigated, but, considering that PrPC is bound to membranes in often highly oxidizing environments,
modifications by lipid-derived aldehydes are likely to be present in PrPC and, possibly, in PrPSc at low levels.
5.4. Enzymatic modifications
Proteins are subject to many enzymatic post-translational modifications. Small amounts of hydroxylation at Pro 44 were found in
PrPSc from the brains of infected mice [109]. This modification is likely a consequence of this region present in a polyproline II
structure similar to collagen [110] since collagen-specific prolyl 4-hydroxylase modifies the proline residues in this conformation.Acknowledgments
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